Is there a role for minimal residual disease levels in the treatment of ALL patients who receive allogeneic stem cells?

@article{Schilham2005IsTA,
  title={Is there a role for minimal residual disease levels in the treatment of ALL patients who receive allogeneic stem cells?},
  author={Marco W Schilham and Adriana Balduzzi and Peter Bader},
  journal={Bone Marrow Transplantation},
  year={2005},
  volume={35},
  pages={S49-S52}
}
Summary:Relapse is the major complication after allogeneic stem cell transplantation (SCT) for acute lymphoblastic leukemia (ALL) in children. Since it has been possible to measure minimal residual disease (MRD) by real-time quantitative polymerase chain reaction, this parameter is used more frequently in the treatment of ALL. In this article, the role of MRD and chimerism in the treatment and monitoring of pediatric transplantation recipients is described. Pre-SCT MRD levels can predict the… CONTINUE READING

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
8 Extracted Citations
13 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-8 of 8 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 13 references

residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL. Leukemia 2002a; 16: 1432–1436

  • P Bader, J Beck, A Frey
  • 2002

Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood

  • JJ van Dongen, T Seriu, ER Panzer-Grumayer
  • Lancet
  • 1998

Similar Papers

Loading similar papers…